Promis Neurosciences announced preclinical programs targeting TDP-43 in ALS, antibody therapies for early Alzheimer's, and alpha-synuclein.
1 report, 1 independent
Updated Aug 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Promis Neurosciences announced preclinical programs targeting TDP-43 in ALS, antibody therapies for early Alzheimer's, and alpha-synuclein.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Als
river in Vienna
Nothing else this week.